TrialThe Lancet. Oncology2020

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Joaquin Mateo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.